Lumen - Biologic Drug for Metabolic Disease

Cardiometabolic disease (CMD)—a cluster of related conditions that includes obesity, diabetes, and cardiovascular disease—afflicts hundreds of millions of people worldwide, and the associated health and economic burdens continue to grow. An estimated 17.9 million people died from CMD in 2019, representing nearly a third of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Today, over three quarters of deaths from cardiovascular diseases take place in low- and middle-income countries. Lumen is collaborating with Novo Nordisk, a global leader in CMD, to develop metabolically active molecules produced and delivered using spirulina.